Drugs / VIR-2218
VIR-2218
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06070051 | Sep 2023 → Mar 2026 overdue | chronic hepatitis B virus infection | Virion Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05844228 | Jun 2023 → Mar 2025 | impaired renal function disease | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05484206 | Sep 2022 → Sep 2026 expected | cirrhosis of liver | Vir Biotechnology, Inc. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05612581 | May 2023 → Oct 2024 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03672188 | Nov 2018 → Sep 2020 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07142811 | Aug 2025 → Nov 2026 expected | viral hepatitis | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06092333 | Jan 2025 → Feb 2028 expected | chronic hepatitis B virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT05461170 | Sep 2022 → Nov 2031 expected | hepatitis D virus infection | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04891770 | Aug 2021 → Jan 2024 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04856085 | Jul 2021 → Mar 2026 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04749368 | Apr 2021 → Jul 2023 | chronic hepatitis B virus infection | Brii Biosciences Limited | Completed | No outcome recorded |
| Phase 2 | NCT04507269 | Aug 2020 → Sep 2021 | chronic hepatitis B virus infection | Brii Biosciences Limited | Completed | No outcome recorded |
| Phase 2 | NCT04412863 | Jul 2020 → Mar 2024 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07128550 | Jul 2025 → Dec 2026 expected | viral hepatitis | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06903338 | Mar 2025 → Dec 2026 expected | viral hepatitis | Vir Biotechnology, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-11-26 | Alnylam Pharmaceuticals | Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 alnylam.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIR-2218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844228 ↗ |
| Known as | BRII-835 | “HBV-targeted siRNA elebsiran (BRII-835)” PMID 40043858 ↗ Mar 2025 |
| Known as | elebsiran | “VIR-2218 (elebsiran), a small interfering RNA agent against HBV transcripts, reduces HBsAg concentrations.” PMID 39389081 ↗ Oct 20244“HBV-targeted siRNA elebsiran (BRII-835)” PMID 40043858 ↗ Mar 2025 |
| Action | Inhibit | “VIR-2218 was designed to silence HBV transcripts” PMID 34741731 ↗ Nov 2021 |
| Modality | Small interfering RNA (siRNA) | “a small interfering RNA agent against HBV transcripts” PMID 39389081 ↗ Oct 2024 |
| Route | Subcutaneous | “VIR-2218 given by subcutaneous injection” NCT03672188 ↗ |